The ODPRN conducted a drug class review on inhaled corticosteroids plus long-acting beta 2-agonists (ICS+LABA) combination products for the management of patients with asthma and chronic obstructive pulmonary disease (COPD), as well as long-acting muscarinic antagonists (LAMAs) for COPD. All three reviews were conducted between November 2013 and April 2015.
Please view the final documents for each review below.
Respiratory Reviews
| Reimbursement Option Recommendations |
|---|
| Final Reimbursement Option Recommendations |
| Citizen's Panel |
|---|
| Respiratory Reviews Citzen's Panel Report |
| Final Publications |
|---|
| Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis |
ICS + LABA for COPD: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
ICS + LABA for Asthma: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
| Stakeholder Feedback |
|---|
| Comments from stakeholder on the draft report for ICS+LABAs for asthma |
LAMAs for COPD: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
| Stakeholder Feedback |
|---|
| Comments from stakeholders on draft Reimbursement Option Recommendations |
| Comments from stakeholder on the draft report for LAMAs for COPD |
Any questions? Contact us at info@odprn.ca.